Is Bristol-Myers Squibb Company (BMY) the Best Wide Moat Stock to Invest In?
We recently published a list of 10 Best Wide Moat Stocks to Invest In. In this article, we are going to take a look at where Bristol-Myers Squibb Company (NYSE:BMY) stands against other best wide moat stocks to invest in.
Bristol Myers Squibb call volume above normal and directionally bullish
Bullish option flow detected in Bristol Myers ( BMY) Squibb with 17,611 calls trading, 2.0x expected, and implied vol increasing over 1 point to 29.73%. May-25 67.5 calls and Aug-25 45 puts are the most active options, with total volume in those strikes near 9,400 contracts. The Put/Call Ratio is 0.61. Earnings are expected on February 6th.
Bristol Myers Squibb Co. stock underperforms Tuesday when compared to competitors
Bristol Myers Squibb Co. closed 3.24% short of its 52-week high of $61.10, which the company reached on January 27th.
Bristol-Myers Squibb (BMY) to Release Earnings on Thursday
Bristol-Myers Squibb (NYSE:BMY – Get Free Report) is expected to be issuing its quarterly earnings data before the market opens on Thursday, February 6th. Analysts expect the company to announce earnings of $1.
Jefferies Keeps Their Buy Rating on Bristol-Myers Squibb (BMY)
Jefferies analyst Akash Tewari maintained a Buy rating on Bristol-Myers Squibb (BMY – Research Report) on February 3 and set a price target of
Bristol-Myers Squibb's SWOT analysis: stock outlook mixed amid pipeline progress
Bristol-Myers Squibb (NYSE:BMY), a global biopharmaceutical giant with a market capitalization of $120.8 billion, finds itself at a critical juncture as it navigates a complex landscape of opportunities and challenges.
R Squared Ltd Makes New Investment in Bristol-Myers Squibb (NYSE:BMY)
R Squared Ltd purchased a new position in Bristol-Myers Squibb (NYSE:BMY – Free Report) in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC).
Bristol-Myers Squibb Q4 2024 Earnings Preview: Strong product sales to continue into 2025
Bristol-Myers Squibb Company  (NYSE:BMY) is scheduled to announce Q4 earnings results on Thursday, February 6th, before ...
Earnings To Watch: Bristol-Myers Squibb (BMY) Reports Q4 Results Tomorrow
Biopharmaceutical company Bristol Myers Squibb (NYSE:BMY) will be reporting results tomorrow before the bell. Here’s what you ...
FiercePharma1d
Bristol Myers Squibb, Kyowa Kirin layoffs hit 119 in New Jersey amid separate restructuring campaigns
As the major cost-cutting initiative at Bristol Myers Squibb rolls on, the company has launched another round of layoffs in ...
2 High-Yield Dividend Stocks to Hold Through 2025 and Beyond
Such companies can be wonderful options for income-seeking investments. If you're in the market for that combo, let's ...
Bristol-Myers Squibb: Too Valuable Not To Hold This Pharma Gem, But Debt Challenges Remain
Bristol-Myers Squibb gets rated a hold, as I see future value in its clinical portfolio and pipeline, particularly ...
planadviser.com8d
Industry Groups Push to Dismiss PRT Lawsuit Against Bristol-Myers Squibb
In an amicus brief, several advocacy groups warned that letting the lawsuit proceed past a motion to dismiss could open the ...
Cantor Fitzgerald lifts Bristol-Myers price target to $55
Cantor Fitzgerald updated its financial model for Bristol-Myers Squibb Co. (NYSE:BMY), leading to an increased price target on the company's stock. Analysts at the firm now see the price target at $55 ...
Zacks Research Issues Negative Outlook for BMY Earnings
Equities researchers at Zacks Research dropped their Q2 2025 EPS estimates for shares of Bristol-Myers Squibb in a note issued to investors on Wednesday, January 29th. Zacks Research analyst E. Bagri ...